Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (2476)	2/22/1998 10:14:00 PM
From: Tokyo VD	Read Replies (1) \| Respond to of 7041

BigKNY, You shouldn't be surprised that the Zonagen promoters have used the lay press once again to erroneously report its misinformation. Once again, it proves that this "news" is more related to stock's promotion than the science behind it. If it wasn't then we would see peer review studies published on the drug and its trials. To this end, what about Newsweek going to press with inaccurate reports of Vasomax success rates in the 60-80% rate? This was inaccurate and unsupported, but it didn't stop Zonagen's supporters from providing this information to Newsweek and Newsweek running it (the reporter has refused to acknowledge his source for this information despite requests to Newsweek's legal counsel). Tokyo